Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b single-blind, placebo-controlled, and proof-of-concept study designed to establish the ability of RLYB212 to rapidly eliminate transfused HPA-1a positive platelets from the circulation of HPA-1a negative healthy male volunteers.

Next Previous
Trial Profile

A Phase 1b single-blind, placebo-controlled, and proof-of-concept study designed to establish the ability of RLYB212 to rapidly eliminate transfused HPA-1a positive platelets from the circulation of HPA-1a negative healthy male volunteers.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RLYB 212 (Primary)
  • Indications Haemolytic disease of newborn; Neonatal alloimmune thrombocytopenia; Thrombocytopenia
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept

Most Recent Events

  • 29 Aug 2024 Results presented in the Rallybio Media Release.
  • 29 Aug 2024 According to a Rallybio media release, data from the trial were published in the Thrombosis and Haemostasis.
  • 08 Aug 2024 According to a Rallybio media release, additional data from this study is expected in in the second half of 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top